Beaufort Securities reaffirmed their speculative buy rating on shares of Amryt Pharma PLC (LON:FAST) in a report issued on Wednesday, StockTargetPrices.com reports. Beaufort Securities currently has a GBX 62 ($0.81) price target on the stock.

Separately, Stifel Nicolaus reaffirmed a buy rating and issued a GBX 60 ($0.78) price objective on shares of Amryt Pharma PLC in a research note on Monday, April 24th.

Amryt Pharma PLC (LON:FAST) opened at 2.97 on Wednesday. The company has a 50 day moving average of GBX 2.91 and a 200 day moving average of GBX 2.54. Amryt Pharma PLC has a 52 week low of GBX 1.85 and a 52 week high of GBX 3.90.

WARNING: “Amryt Pharma PLC’s (LON:FAST) “Speculative Buy” Rating Reiterated at Beaufort Securities” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/amryt-pharma-plcs-lonfast-speculative-buy-rating-reiterated-at-beaufort-securities/1462120.html.

Amryt Pharma PLC Company Profile

Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company’s lead products include AP 101 and AP102.

Stock Target Prices

Receive News & Ratings for Amryt Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.